David Malitz, MD
Ophthalmology · Evansville, INNPI 1982671194
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,295 of the $12,336 with a category attached, or 83.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $38.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$972
- Bausch & Lomb, A Division Of Bausch Health US, LLC$676
- Novartis$602
- plus $5K from 26 others
What the payments were for
- Food & beverage$10,29583%
- Education$1001%
- Gifts$450%
- Other$1,89615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 24 | $2,456 |
| AbbVie(2 entities) | 67 | $1,615 |
| Johnson & Johnson Surgical Vision, Inc. | 40 | $1,422 |
| Alcon | 33 | $972 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 30 | $676 |
| Novartis | 29 | $602 |
| Eyevance Pharmaceuticals LLC | 3 | $444 |
| Harrow Eye, LLC | 4 | $409 |
| Sun Pharmaceutical Industries Inc. | 12 | $339 |
| Kala Pharmaceuticals, Inc. | 6 | $329 |
| Biotissue Holdings Inc. | 6 | $292 |
| Eyepoint US, Inc. | 5 | $290 |
| Rxsight Inc | 5 | $271 |
| Aerie Pharmaceuticals, Inc. | 5 | $265 |
| Tarsus Pharmaceuticals, Inc. | 6 | $264 |
| Mallinckrodt Enterprises LLC | 3 | $259 |
| NEW World Medical,inc. | 10 | $241 |
| Amgen(2 entities) | 4 | $203 |
| Ivantis, Inc | 3 | $190 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 5 | $104 |
| ANI Pharmaceuticals, Inc. | 2 | $93 |
| Astellas Pharma US Inc | 1 | $88 |
| Regeneron | 1 | $75 |
| Regeneron Healthcare Solutions, Inc. | 1 | $71 |
| Omeros Corporation | 1 | $52 |
| Ocular Therapeutix, Inc. | 3 | $41 |
| Sight Sciences, Inc. | 2 | $39 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Shire North American Group Inc | 2 | $28 |
| Medline Industries LP | 1 | $26 |
| Optos, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ScoutPro Osmolarity System$1,896
- Tecnis IOL$341
- XIIDRA$274
- VEVYE$258
- DURYSTA$257
- Prokera$250
- AmnioGraft$250
- Rocklatan$248
- ACTHAR$236
- DEXYCU$234
- Flarex$212
- MIEBO$150
- Zerviate$148
- INVELTYS$140
- Luxor$139
- Hydrus Microstent$126
- IHEEZO$125
- QULIPTA$122
- UBRELVY$122
- TEPEZZA$122
How this compares
$12,336 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 62 | $25,930 |
| RestasisCyclosporine | 26 | $25,578 |
| XiidraLifitegrast | 24 | $15,423 |
| LumiganBimatoprost | 29 | $15,044 |
| Prednisolone Acetate | 301 | $12,524 |
| ProlensaBromfenac Sodium | 31 | $10,537 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $7,358 |
| VyzultaLatanoprostene Bunod | 21 | $5,943 |
| Latanoprost | 514 | $4,359 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 51 | $3,864 |
| Ofloxacin | 283 | $3,121 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 20 | $2,278 |
| Diclofenac Sodium | 199 | $2,168 |
| Fluorometholone | 20 | $1,591 |
| TafluprostTafluprost/Pf | 12 | $1,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,615 | $47,98078 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $265 | $25,93062 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $2,456 | $21,36745 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $676 | $10,53731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Evansville
- Omar DukarEvansville$43K
- Dwight SilveraEvansville$28K
- Andrew StrandEvansville$12K
- Drew SommervilleEvansville$8K
- Matthew BoyerEvansville$6K
- Karishma HabbuEvansville$4K
- Jonathan WeyerEvansville$4K
- Sally PrimusEvansville$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.